Market Overview

Congenica Appoints Wendy Britten as Chief Financial Officer


the global provider of clinical genomics interpretation software, today
announced the appointment of Mrs Wendy Britten as its new Chief
Financial Officer (CFO), effective 1st September, 2018. Mrs
Britten will have overall control and responsibility for all financial
aspects of the business, and will play a key role in business
development and fundraising activities.

A finance professional with experience in senior financial leadership
roles, Mrs Britten joins Congenica from AstraZeneca, where she headed up
the Group Finance Business Performance team, working with the Senior
Executive team. Prior to this, her career at PricewaterhouseCoopers
(PwC) started in Audit, progressing ultimately to Director of M&A in
both London and New York. She is a qualified Chartered Accountant and
holds a BSc in Mathematics from the University of Sheffield.

David Atkins, CEO of Congenica, said:

"I am delighted to welcome Wendy to Congenica. She joins our Senior
Management team at a pivotal time in the Company's development. She
brings financial leadership and business development expertise, as we
move forward commercially on the back of our successful series B
financing last year. Her international experience will support our
operational expansion in the UK and across Europe, China and the US."

Dr Andy Richards, Chairman of Congenica, said:

"Mrs Britten's ambitious and energetic outlook and considerable
experience adds to our skills as Congenica continues its successful
trajectory in the international genomics sector. Her appointment
underlines our ambition to become a significant global player, providing
a critical service that enables genomics to deliver on its promise in
human healthcare."

Led by CEO
David Atkins,
the past year has seen significant advancements for
Congenica, including a successful Series
B financing round
that raised USD $13.5M from leading China- and
UK-based investors. Congenica's gold-standard Sapientiaclinical
genomics analysis platform is currently supporting several major
projects globally – including Genomics England's ground-breaking 100K
China's national 100K Wellness project

Commenting on her appointment, Congenica's new CFO Mrs Wendy Britten

"I am looking forward to the opportunities that joining the team at
Congenica offers. With a strong commitment to positively impacting
patient's lives, Congenica is poised for substantial growth. The field
of genomic medicine has the potential to revolutionise our approach to
rare genetic disease diagnosis and management, as well as in other areas
of personalised medicine."

- Ends -

About Congenica

Congenica is the developer of gold-standard clinical genomic diagnostic
decision support platform, Sapientia. Based in Cambridge, UK, and born
out of pioneering research from the Sanger Institute, Congenica is
committed to supporting clinicians and doctors to quickly and accurately
diagnose rare and genetic diseases to revolutionise treatments, design
trials and aid in drug development.

View Comments and Join the Discussion!